A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Abiraterone (Primary) ; Ipatasertib (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical; Roche
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 22 Aug 2017 Planned End Date changed from 24 Aug 2023 to 9 Sep 2023.
- 12 May 2017 Status changed from not yet recruiting to recruiting.